173 related articles for article (PubMed ID: 2902918)
1. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
Ellis TM; Creekmore SP; McMannis JD; Braun DP; Harris JA; Fisher RI
Cancer Res; 1988 Nov; 48(22):6597-602. PubMed ID: 2902918
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
4. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
5. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
6. Two populations of CD56 (Leu-19)+/CD16+ cells in bone marrow transplant recipients.
Gottschalk LR; Bray RA; Kaizer H; Gebel HM
Bone Marrow Transplant; 1990 Apr; 5(4):259-64. PubMed ID: 1692496
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
8. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
Ellis TM; Fisher RI
J Immunol; 1989 Apr; 142(8):2949-54. PubMed ID: 2467946
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
Urba WJ; Steis RG; Longo DL; Kopp WC; Maluish AE; Marcon L; Nelson DL; Stevenson HC; Clark JW
Cancer Res; 1990 Jan; 50(1):185-92. PubMed ID: 2293554
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
11. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of human FcRIII-positive and negative natural killer cells.
Nagler A; Lanier LL; Cwirla S; Phillips JH
J Immunol; 1989 Nov; 143(10):3183-91. PubMed ID: 2530273
[TBL] [Abstract][Full Text] [Related]
13. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
Lanier LL; Le AM; Civin CI; Loken MR; Phillips JH
J Immunol; 1986 Jun; 136(12):4480-6. PubMed ID: 3086432
[TBL] [Abstract][Full Text] [Related]
14. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
15. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.
Lanier LL; Le AM; Cwirla S; Federspiel N; Phillips JH
Fed Proc; 1986 Nov; 45(12):2823-8. PubMed ID: 3095151
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
17. The CD56 adhesion molecule is the major determinant for detecting non-major histocompatibility complex-restricted cytotoxic mononuclear cells from the intestinal lamina propria.
Van Tol EA; Verspaget HW; Peña AS; Kraemer CV; Lamers CB
Eur J Immunol; 1992 Jan; 22(1):23-9. PubMed ID: 1370415
[TBL] [Abstract][Full Text] [Related]
18. Increased cytotoxicity and CD16 (Leu 11) expression in long-term, IL-2-activated human peripheral blood mononuclear cells.
Podack ER; Penichet KO; Lin BY; Chiao JW; Mittelman A
Blood Cells; 1987; 13(1-2):117-22. PubMed ID: 3311212
[TBL] [Abstract][Full Text] [Related]
19. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
20. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
